AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (1.3 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases

Beijian Zhanga,b,d,e,1, Hao Jianga,b,d,e,1, Zhen Donga,b,d,e, Aijun Suna,b,c,d,e( ), Junbo Gea,b,c,d,e( )
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, PR China
Shanghai Institute of Cardiovascular Diseases, Shanghai, 200003, PR China
Institutes of Biomedical Sciences, Fudan University, Shanghai, 200433, PR China
NHC Key Laboratory of Viral Heart Diseases, Shanghai, 200032, PR China
Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, Shanghai, 200032, PR China

1 Beijian Zhang and Hao Jiang contributed equally to this article.]]>

Show Author Information

Abstract

N6-methyladenosine (m6A) RNA methylation is an emerging area of epigenetics, which is a reversible and dynamic modification mediating by 'writers' (methylase, adding methyl groups, METTL3, METTL14, and WTAP), 'erasers' (demethylase, deleting methyl groups, FTO and ALKBH5), and 'readers' (YTHDF1-3, YTHDC1 and YTHDC2). Recent studies in human, animal models and cell levels have disclosed a critical role of m6A modification in regulating the homeostasis of metabolic processes and cardiovascular function. Evidence from these studies identify m6A as a candidate of biomarker and therapeutic target for metabolic abnormality and cardiovascular diseases (CVD). Comprehensive understanding of the complexity of m6A regulation in metabolic diseases and CVD will be helpful for us to understand the pathogenesis of CVD. In this review, we discuss the regulatory role of m6A in metabolic abnormality and CVD. We will emphasize the clinical relevance of m6A dysregulation in CVD.

Keywords

Cardiovascular diseaseHeart failureMyocardial infarctionMetabolic syndromeFTOMETTL3N6-methyladenosineRNA epigenetics

References

1

van der Harst P, de Windt LJ, Chambers JC. Translational perspective on epigenetics in cardiovascular disease. J Am Coll Cardiol. 2017;70(5): 590-606.
Crossref Google Scholar
2

Zhong J, Agha G, Baccarelli AA. The role of DNA methylation in cardiovascular risk and disease: methodological aspects, study design, and data analysis for epidemiological studies. Circ Res. 2016;118(1): 119-131.
Crossref Google Scholar
3

Kuznetsova T, Prange KHM, Glass CK, de Winther MPJ. Transcriptional and epigenetic regulation of macrophages in atherosclerosis. Nat Rev Cardiol. 2020;17(4): 216-228.
Crossref Google Scholar
4

Agha G, Mendelson MM, Ward-Caviness CK, et al. Blood leukocyte DNA methylation predicts risk of future myocardial infarction and coronary heart disease. Circulation. 2019;140(8): 645-657.
Crossref Google Scholar
5

Li P, Ge J, Li H. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease. Nat Rev Cardiol. 2020;17(2): 96-115.
Crossref Google Scholar
6

Ng RK, Gurdon JB. Epigenetic inheritance of cell differentiation status. Cell Cycle. 2008;7(9): 1173-1177.
Crossref Google Scholar
7

Gilbert WV, Bell TA, Schaening C. Messenger RNA modifications: form, distribution, and function. Science. 2016;352(6292): 1408-1412.
Crossref Google Scholar
8

Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7): 1187-1200.
Crossref Google Scholar
9

Cowling VH. Regulation of mRNA cap methylation. Biochem J. 2009;425(2): 295-302.
Crossref Google Scholar
10

Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2017;18(1): 31-42.
Crossref Google Scholar
11

Liu N, Pan T. N6-methyladenosine-encoded epitranscriptomics. Nat Struct Mol Biol. 2016;23(2): 98-102.
Crossref Google Scholar
12

Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397): 201-206.
Crossref Google Scholar
13

Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149(7): 1635-1646.
Crossref Google Scholar
14

Choe J, Lin S, Zhang W, et al. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018;561(7724): 556-560.
Crossref Google Scholar
15

Yoon KJ, Ringeling FR, Vissers C, et al. Temporal control of mammalian cortical neurogenesis by m(6)A methylation. Cell. 2017;171(4): 877-889.
Crossref Google Scholar
16

Mathiyalagan P, Adamiak M, Mayourian J, et al. FTO-dependent N(6)-methyladenosine regulates cardiac function during remodeling and repair. Circulation. 2019;139(4): 518-532.
Crossref Google Scholar
17

Dorn LE, Lasman L, Chen J, et al. The N(6)-methyladenosine mRNA methylase METTL3 controls cardiac homeostasis and hypertrophy. Circulation. 2019;139(4): 533-545.
Crossref Google Scholar
18

Perry RP, Kelley DE, Friderici K, Rottman F. The methylated constituents of L cell messenger RNA: evidence for an unusual cluster at the 5′ terminus. Cell. 1975;4(4): 387-394.
Crossref Google Scholar
19

Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10): 3971-3975.
Crossref Google Scholar
20

Dubin DT, Taylor RH. The methylation state of poly A-containing messenger RNA from cultured hamster cells. Nucleic Acids Res. 1975;2(10): 1653-1668.
Crossref Google Scholar
21

Adams JM, Cory S. Modified nucleosides and bizarre 5′-termini in mouse myeloma mRNA. Nature. 1975;255(5503): 28-33.
Crossref Google Scholar
22

Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m⁶A RNA methylation. Nat Rev Genet. 2014;15(5): 293-306.
Crossref Google Scholar
23

Liu J, Yue Y, Han D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2): 93-95.
Crossref Google Scholar
24

Wang X, Feng J, Xue Y, et al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature. 2016;534(7608): 575-578.
Crossref Google Scholar
25

Schwartz S, Mumbach MR, Jovanovic M, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5′ sites. Cell Rep. 2014;8(1): 284-296.
Crossref Google Scholar
26

Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24(2): 177-189.
Crossref Google Scholar
27

Pendleton KE, Chen B, Liu K, et al. The U6 snRNA m(6)A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 2017;169(5): 824-835.
Crossref Google Scholar
28

Patil DP, Chen CK, Pickering BF, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620): 369-373.
Crossref Google Scholar
29

Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12): 885-887.
Crossref Google Scholar
30

Fu Y, Jia G, Pang X, et al. FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA. Nat Commun. 2013;4, e1798.
Crossref Google Scholar
31

Mauer J, Luo X, Blanjoie A, et al. Reversible methylation of m(6)A(m) in the 5′ cap controls mRNA stability. Nature. 2017;541(7637): 371-375.
Crossref Google Scholar
32

Zheng G, Dahl JA, Niu Y, et al. Sprouts of RNA epigenetics: the discovery of mammalian RNA demethylases. RNA Biol. 2013;10(6): 915-918.
Crossref Google Scholar
33

Theler D, Dominguez C, Blatter M, Boudet J, Allain FH. Solution structure of the YTH domain in complex with N6-methyladenosine RNA: a reader of methylated RNA. Nucleic Acids Res. 2014;42(22): 13911-13919.
Crossref Google Scholar
34

Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481): 117-120.
Crossref Google Scholar
35

Wang X, Zhao BS, Roundtree IA, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161(6): 1388-1399.
Crossref Google Scholar
36

Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27(3): 315-328.
Crossref Google Scholar
37

Xiao W, Adhikari S, Dahal U, et al. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016;61(4): 507-519.
Crossref Google Scholar
38

Roundtree IA, Luo GZ, Zhang Z, et al. YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. Elife. 2017;6, e31311.
Crossref Google Scholar
39

Shima H, Matsumoto M, Ishigami Y, et al. S-adenosylmethionine synthesis is regulated by selective N(6)-adenosine methylation and mRNA degradation involving METTL16 and YTHDC1. Cell Rep. 2017;21(12): 3354-3363.
Crossref Google Scholar
40

Tanabe A, Tanikawa K, Tsunetomi M, et al. RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. Cancer Lett. 2016;376(1): 34-42.
Crossref Google Scholar
41

Hsu PJ, Zhu Y, Ma H, et al. Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27(9): 1115-1127.
Crossref Google Scholar
42

Meyer KD, Patil DP, Zhou J, et al. 5′ UTR m(6)A promotes cap-independent translation. Cell. 2015;163(4): 999-1010.
Crossref Google Scholar
43

Cieniková Z, Damberger FF, Hall J, Allain FH, Maris C. Structural and mechanistic insights into poly(uridine) tract recognition by the hnRNP C RNA recognition motif. J Am Chem Soc. 2014;136(41): 14536-14544.
Crossref Google Scholar
44

Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015;518(7540): 560-564.
Crossref Google Scholar
45

Huang H, Weng H, Sun W, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3): 285-295.
Crossref Google Scholar
46

Wu R, Li A, Sun B, et al. A novel m(6)A reader Prrc2a controls oligodendroglial specification and myelination. Cell Res. 2019;29(1): 23-41.
Crossref Google Scholar
47

Shi S, Kong N, Feng C, et al. Drug delivery strategies for the treatment of metabolic diseases. Adv Healthc Mater. 2019;8(12), e1801655.
Crossref Google Scholar
48

Paramasivam A, Vijayashree Priyadharsini J, Raghunandhakumar S. N6-adenosine methylation (m6A): a promising new molecular target in hypertension and cardiovascular diseases. Hypertens Res. 2020;43(2): 153-154.
Crossref Google Scholar
49

Wu Q, Yuan X, Han R, Zhang H, Xiu R. Epitranscriptomic mechanisms of N6-methyladenosine methylation regulating mammalian hypertension development by determined spontaneously hypertensive rats pericytes. Epigenomics. 2019;11(12): 1359-1370.
Crossref Google Scholar
50

Su H, Wang G, Wu L, Ma X, Ying K, Zhang R. Transcriptome-wide map of m(6)A circRNAs identified in a rat model of hypoxia mediated pulmonary hypertension. BMC Genomics. 2020;21(1), e39.
Crossref Google Scholar
51

Mo XB, Lei SF, Zhang YH, Zhang H. Examination of the associations between m(6)A-associated single-nucleotide polymorphisms and blood pressure. Hypertens Res. 2019;42(10): 1582-1589.
Crossref Google Scholar
52

Meyer TE, Shiffman D, Morrison AC, et al. GOSR2 Lys67Arg is associated with hypertension in whites. Am J Hypertens. 2009;22(2): 163-168.
Crossref Google Scholar
53

He D, Fu M, Miao S, Hotta K, Chandak GR, Xi B. FTO gene variant and risk of hypertension: a meta-analysis of 57, 464 hypertensive cases and 41, 256 controls. Metabolism. 2014;63(5): 633-639.
Crossref Google Scholar
54

Marcadenti A, Fuchs FD, Matte U, Sperb F, Moreira LB, Fuchs SC. Effects of FTO RS9939906 and MC4R RS17782313 on obesity, type 2 diabetes mellitus and blood pressure in patients with hypertension. Cardiovasc Diabetol. 2013;12, e103.
Crossref Google Scholar
55

Zotova TY, Lapaev NN, Azova MM, et al. Distribution of polymorphisms of the Renin-angiotensin system genes (ACE, AGT, and AGTR1), ITGB3, and FTO in pregnant patients with hypertensive disorders. Bull Exp Biol Med. 2019;167(1): 74-78.
Crossref Google Scholar
56

Khoshi A, Bajestani MK, Shakeri H, Goodarzi G, Azizi F. Association of Omentin rs2274907 and FTO rs9939609 gene polymorphisms with insulin resistance in Iranian individuals with newly diagnosed type 2 diabetes. Lipids Health Dis. 2019; 18(1), e142.
Crossref Google Scholar
57

Hjort R, Löfvenborg JE, Ahlqvist E, et al. Interaction between overweight and genotypes of HLA, TCF7L2, and FTO in relation to the risk of latent autoimmune diabetes in adults and type 2 diabetes. J Clin Endocrinol Metab. 2019;104(10): 4815-4826.
Crossref Google Scholar
58

Nasser FA, Algenabi AA, Hadi NR, Hussein MK, Fatima G, Al-Aubaidy HA. The association of the common fat mass and obesity associated gene polymorphisms with type 2 diabetes in obese Iraqi population. Diabetes Metab Syndr. 2019;13(4): 2451-2455.
Crossref Google Scholar
59

Naaz K, Kumar A, Choudhury I. Assessment of FTO gene polymorphism and its association with type 2 diabetes mellitus in North Indian populations. Indian J Clin Biochem. 2019;34(4): 479-484.
Crossref Google Scholar
60

Beysel S, Pinarli FA, Eyerci N, et al. HNF1A gene p. I27L is associated with co-existing preeclampsia in gestational diabetes mellitus. Gynecol Endocrinol. 2020;36(6): 530-534.
Crossref Google Scholar
61

Yang Y, Shen F, Huang W, et al. Glucose is involved in the dynamic regulation of m6A in patients with type 2 diabetes. J Clin Endocrinol Metab. 2019;104(3): 665-673.
Crossref Google Scholar
62

Peng S, Xiao W, Ju D, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci Transl Med. 2019;11(488), eaau7116.
Crossref Google Scholar
63

Shen F, Huang W, Huang JT, et al. Decreased N(6)-methyladenosine in peripheral blood RNA from diabetic patients is associated with FTO expression rather than ALKBH5. J Clin Endocrinol Metab. 2015;100(1): E148-E154.
Crossref Google Scholar
64

Zhou J, Wan J, Shu XE, et al. N(6)-Methyladenosine guides mRNA alternative translation during integrated stress response. Mol Cell. 2018;69(4): 636-647.
Crossref Google Scholar
65

Li K, Zhang J, Yu J, et al. MicroRNA-214 suppresses gluconeogenesis by targeting activating transcriptional factor 4. J Biol Chem. 2015;290(13): 8185-8195.
Crossref Google Scholar
66

De Jesus DF, Kulkarni RN. Epigenetic modifiers of islet function and mass. Trends Endocrinol Metab. 2014;25(12): 628-636.
Crossref Google Scholar
67

De Jesus DF, Zhang Z, Kahraman S, et al. m(6)A mRNA methylation regulates human beta-cell biology in physiological states and in type 2 diabetes. Nat Metab. 2019;1(8): 765-774.
Crossref Google Scholar
68

Wang Y, Sun J, Lin Z, et al. m(6)A mRNA methylation controls functional maturation in neonatal murine β cells. Diabetes. 2020;69(8): 1708-1722.
Crossref Google Scholar
69

Xie W, Ma LL, Xu YQ, Wang BH, Li SM. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. Biochem Biophys Res Commun. 2019;518(1): 120-126.
Crossref Google Scholar
70

Krüger N, Biwer LA, Good ME, et al. Loss of endothelial FTO antagonizes obesity-induced metabolic and vascular dysfunction. Circ Res. 2020;126(2): 232-242.
Crossref Google Scholar
71

Hu F, Tong J, Deng B, Zheng J, Lu C. MiR-495 regulates macrophage M1/M2 polarization and insulin resistance in high-fat diet-fed mice via targeting FTO. Pflugers Arch. 2019;471(11–12): 1529-1537.
Crossref Google Scholar
72

Mussa BM, Taneera J, Mohammed AK, Srivastava A, Mukhopadhyay D, Sulaiman N. Potential role of hypothalamic microRNAs in regulation of FOS and FTO expression in response to hypoglycemia. J Physiol Sci. 2019;69(6): 981-991.
Crossref Google Scholar
73

Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793): 815-825.
Crossref Google Scholar
74

Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J. 2015;36(9): 551-559.
Crossref Google Scholar
75

Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39(6): 724-726.
Crossref Google Scholar
76

Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826): 889-894.
Crossref Google Scholar
77

Ningombam SS, Chhungi V, Newmei MK, et al. Differential distribution and association of FTO rs9939609 gene polymorphism with obesity: a cross-sectional study among two tribal populations of India with East-Asian ancestry. Gene. 2018;647: 198-204.
Crossref Google Scholar
78

Yako YY, Echouffo-Tcheugui JB, Balti EV, et al. Genetic association studies of obesity in Africa: a systematic review. Obes Rev. 2015;16(3): 259-272.
Crossref Google Scholar
79

Hebbar P, Abu-Farha M, Mohammad A, et al. FTO variant rs1421085 associates with increased body weight, soft lean mass, and total body water through interaction with ghrelin and apolipoproteins in Arab population. Front Genet. 2019;10, e1411.
Crossref Google Scholar
80

Klungland A, Dahl JA. Dynamic RNA modifications in disease. Curr Opin Genet Dev. 2014;26: 47-52.
Crossref Google Scholar
81

da Fonseca ACP, Abreu GM, Zembrzuski VM, et al. The association of the fat mass and obesity-associated gene (FTO) rs9939609 polymorphism and the severe obesity in a Brazilian population. Diabetes Metab Syndr Obes. 2019;12: 667-684.
Crossref Google Scholar
82

Kaspi A, Khurana I, Ziemann M, et al. Diet during pregnancy is implicated in the regulation of hypothalamic RNA methylation and risk of obesity in offspring. Mol Nutr Food Res. 2018, e1800134.
Crossref Google Scholar
83

Wang Y, Gao M, Zhu F, et al. METTL3 is essential for postnatal development of brown adipose tissue and energy expenditure in mice. Nat Commun. 2020;11(1), e1648.
Crossref Google Scholar
84

Doaei S, Kalantari N, Mohammadi NK, et al. Up-regulation of FTO gene expression was associated with increase in skeletal muscle mass in overweight male adolescents. Arch Med Sci. 2019;15(5): 1133-1137.
Crossref Google Scholar
85

Wang X, Huang N, Yang M, et al. FTO is required for myogenesis by positively regulating mTOR-PGC-1α pathway-mediated mitochondria biogenesis. Cell Death Dis. 2017;8(3), e2702.
Crossref Google Scholar
86

Wu W, Feng J, Jiang D, et al. AMPK regulates lipid accumulation in skeletal muscle cells through FTO-dependent demethylation of N(6)-methyladenosine. Sci Rep. 2017;7, e41606.
Crossref Google Scholar
87

Wu R, Liu Y, Yao Y, et al. FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(10): 1323-1330.
Crossref Google Scholar
88

Wu R, Yao Y, Jiang Q, et al. Epigallocatechin gallate targets FTO and inhibits adipogenesis in an mRNA m(6)A-YTHDF2-dependent manner. Int J Obes (Lond). 2018;42(7): 1378-1388.
Crossref Google Scholar
89

Song T, Yang Y, Wei H, et al. Zfp217 mediates m6A mRNA methylation to orchestrate transcriptional and post-transcriptional regulation to promote adipogenic differentiation. Nucleic Acids Res. 2019;47(12): 6130-6144.
Crossref Google Scholar
90

Wang X, Wu R, Liu Y, et al. m(6)A mRNA methylation controls autophagy and adipogenesis by targeting Atg5 and Atg7. Autophagy. 2020;16(7): 1221-1235.
Crossref Google Scholar
91

Zhao X, Yang Y, Sun BF, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res. 2014;24(12): 1403-1419.
Crossref Google Scholar
92

Merkestein M, Laber S, McMurray F, et al. FTO influences adipogenesis by regulating mitotic clonal expansion. Nat Commun. 2015;6, e6792.
Crossref Google Scholar
93

Wang X, Zhu L, Chen J, Wang Y. mRNA m(6)A methylation downregulates adipogenesis in porcine adipocytes. Biochem Biophys Res Commun. 2015;459(2): 201-207.
Crossref Google Scholar
94

Liu Q, Zhao Y, Wu R, et al. ZFP217 regulates adipogenesis by controlling mitotic clonal expansion in a METTL3-m(6)A dependent manner. RNA Biol. 2019;16(12): 1785-1793.
Crossref Google Scholar
95

Guo L, Li X, Tang QQ. Transcriptional regulation of adipocyte differentiation: a central role for CCAAT/enhancer-binding protein (C/EBP) beta. J Biol Chem. 2015;290(2): 755-761.
Crossref Google Scholar
96

Yao Y, Bi Z, Wu R, et al. METTL3 inhibits BMSC adipogenic differentiation by targeting the JAK1/STAT5/C/EBPbeta pathway via an m(6)A-YTHDF2-dependent manner. FASEB J. 2019;33(6): 7529-7544.
Crossref Google Scholar
97

Wu R, Guo G, Bi Z, et al. m(6)A methylation modulates adipogenesis through JAK2-STAT3-C/EBPbeta signaling. Biochim Biophys Acta Gene Regul Mech. 2019;1862(8): 796-806.
Crossref Google Scholar
98

Cai M, Liu Q, Jiang Q, Wu R, Wang X, Wang Y. Loss of m(6) A on FAM134B promotes adipogenesis in porcine adipocytes through m(6) A-YTHDF2-dependent way. IUBMB Life. 2019;71(5): 580-586.
Crossref Google Scholar
99

Jiang Q, Sun B, Liu Q, et al. MTCH2 promotes adipogenesis in intramuscular preadipocytes via an m(6)A-YTHDF1-dependent mechanism. FASEB J. 2019;33(2): 2971-2981.
Crossref Google Scholar
100

Liu W, Cao H, Yan J, Huang R, Ying H. Micro-managers' of hepatic lipid metabolism and NAFLD. Wiley Interdiscip Rev RNA. 2015;6(5): 581-593.
Crossref Google Scholar
101

Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(8): 948-963.
Crossref Google Scholar
102

Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6): 1138-1153.
Crossref Google Scholar
103

Luo J, Xu L, Li J, Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol. 2015;27(3): 193-199.
Crossref Google Scholar
104

Chen J, Zhou X, Wu W, Wang X, Wang Y. FTO-dependent function of N6-methyladenosine is involved in the hepatoprotective effects of betaine on adolescent mice. J Physiol Biochem. 2015;71(3): 405-413.
Crossref Google Scholar
105

Guo J, Ren W, Li A, et al. Fat mass and obesity-associated gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58(4): 1004-1009.
Crossref Google Scholar
106

Zhang J, Li S, Li J, et al. Expression and significance of fat mass and obesity associated gene and forkhead transcription factor O1 in non-alcoholic fatty liver disease. Chin Med J (Engl). 2014;127(21): 3771-3776.
Google Scholar
107

Sun L, Ling Y, Jiang J, et al. Differential mechanisms regarding triclosan vs. bisphenol A and fluorene-9-bisphenol induced zebrafish lipid-metabolism disorders by RNA-Seq. Chemosphere. 2020;251, e126318.
Crossref Google Scholar
108

Hu Y, Feng Y, Zhang L, et al. GR-mediated FTO transactivation induces lipid accumulation in hepatocytes via demethylation of m(6)A on lipogenic mRNAs. RNA Biol. 2020;17(7): 930-942.
Crossref Google Scholar
109

Li S, Wang X, Zhang J, et al. Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease. Braz J Med Biol Res. 2018;51(8), e7299.
Crossref Google Scholar
110

Chen J, Ning Y, Zhang H, et al. METTL14-dependent m6A regulates vascular calcification induced by indoxyl sulfate. Life Sci. 2019;239, e117034.
Crossref Google Scholar
111

Mo C, Yang M, Han X, et al. Fat mass and obesity-associated protein attenuates lipid accumulation in macrophage foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J Hypertens. 2017;35(4): 810-821.
Crossref Google Scholar
112

Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347): 317-325.
Crossref Google Scholar
113

Bäck M, Yurdagul A Jr, Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7): 389-406.
Crossref Google Scholar
114

Liu Y, Liu Z, Tang H, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA. Am J Physiol Cell Physiol. 2019;317(4): c762-c775.
Crossref Google Scholar
115

Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84(3): 767-801.
Crossref Google Scholar
116

Zhu B, Gong Y, Shen L, et al. Total Panax notoginseng saponin inhibits vascular smooth muscle cell proliferation and migration and intimal hyperplasia by regulating WTAP/p16 signals via m(6)A modulation. Biomed Pharmacother. 2020;124, e109935.
Crossref Google Scholar
117

Bardeesi ASA, Gao J, Zhang K, et al. A novel role of cellular interactions in vascular calcification. J Transl Med. 2017;15(1), e95.
Crossref Google Scholar
118

Zhou T, Han D, Liu J, et al. Factors influencing osteogenic differentiation of human aortic valve interstitial cells. J Thorac Cardiovasc Surg. 2019;158(4): 1-65.
Crossref Google Scholar
119

Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070): 967-974.
Crossref Google Scholar
120

Mo XB, Lei SF, Zhang YH, Zhang H. Detection of m(6)A-associated SNPs as potential functional variants for coronary artery disease. Epigenomics. 2018;10(10): 1279-1287.
Crossref Google Scholar
121

Binder A, Ali A, Chawla R, Aziz HA, Abbate A, Jovin IS. Myocardial protection from ischemia-reperfusion injury post coronary revascularization. Expert Rev Cardiovasc Ther. 2015;13(9): 1045-1057.
Crossref Google Scholar
122

Song H, Feng X, Zhang H, et al. METTL3 and ALKBH5 oppositely regulate m(6)A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Autophagy. 2019;15(8): 1419-1437.
Crossref Google Scholar
123

Ruan Z, Wang S, Yu W, Deng F. LncRNA MALAT1 aggravates inflammation response through regulating PTGS2 by targeting miR-26b in myocardial ischemia-reperfusion injury. Int J Cardiol. 2019;288, e122.
Crossref Google Scholar
124

Yang C, Fan Z, Yang J. m(6)A modification of LncRNA MALAT1: a novel therapeutic target for myocardial ischemia-reperfusion injury. Int J Cardiol. 2020;306(9), e162.
Crossref Google Scholar
125

Saxena R, Weintraub NL, Tang Y. Optimizing cardiac ischemic preconditioning and postconditioning via epitranscriptional regulation. Med Hypotheses. 2020;135, e109451.
Crossref Google Scholar
126

McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365(9474): 1877-1889.
Crossref Google Scholar
127

Berulava T, Buchholz E, Elerdashvili V, et al. Changes in m6A RNA methylation contribute to heart failure progression by modulating translation. Eur J Heart Fail. 2020;22(1): 54-66.
Crossref Google Scholar
128

Hubacek JA, Vymetalova J, Lanska V, Dlouha D. The fat mass and obesity related gene polymorphism influences the risk of rejection in heart transplant patients. Clin Transplant. 2018;32(12), e13443.
Crossref Google Scholar
129

Devaux Y, Nossent AY. A role for m6A RNA methylation in heart failure development?. Eur J Heart Fail. 2020;22(1): 67-69.
Crossref Google Scholar
130

Chen X, Luo Y, Jia G, Liu G, Zhao H, Huang Z. FTO promotes adipogenesis through inhibition of the Wnt/β-catenin signaling pathway in porcine intramuscular preadipocytes. Anim Biotechnol. 2017;28(4): 268-274.
Crossref Google Scholar
131

Ronkainen J, Mondini E, Cinti F, et al. Fto-deficiency affects the gene and MicroRNA expression involved in Brown adipogenesis and browning of white adipose tissue in mice. Int J Mol Sci. 2016;17(11), e1851.
Crossref Google Scholar
Genes & Diseases
Volume 8 Issue 6,
November 2021
Pages 746-758
DOI: 10.1016/j.gendis.2020.07.011
Cite this article:
Zhang B, Jiang H, Dong Z, et al. The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases. Genes & Diseases, 2021, 8(6): 746-758. https://doi.org/10.1016/j.gendis.2020.07.011

279

Views

6

Downloads

62

Crossref

N/A

Web of Science

71

Scopus

0

CSCD

Altmetrics
Received: 09 June 2020
Revised: 21 July 2020
Accepted: 24 July 2020
Published: 31 July 2020
© 2020, Chongqing Medical University. Production and hosting by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return